<DOC>
	<DOCNO>NCT02460276</DOCNO>
	<brief_summary>In trial , patient mantle cell lymphoma include , treatment lenalidomide , rituximab ibrutinib administer induction phase 12 cycle , cycle length 28 day . Patients complete remission , partial response stable disease enter maintenance phase treatment ibrutinib rituximab progression disease . The primary objective evaluate overall response rate , base PET CT .</brief_summary>
	<brief_title>A Trial Ibrutinib , Lenalidomide Rituximab Patients With Relapsed/Refractory Mantle Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Age 18 year Histologically confirm ( accord WHO 2008 , upcoming 2015 classification ) mantle cell lymphoma stage IIIV Received least 1 prior rituximabcontaining chemotherapy regimen Documented relapse disease progression follow last antimantle cell lymphoma treatment At least 1 measurable site disease ( 1.5 cm long axis ) WHO performance status 03 Written inform concent Female subject childbearing potential must : 1 . Understand study medication expect teratogenic effect 2 . Agree use , able comply , highly effective contraception without interruption , 4 week Before start study drug , throughout study drug therapy ( include dose interruption ) 12 month end study drug therapy , even amenorrhoea 3 . Women childbearing potential must negative serum ( betahuman ionic gonadotropin urine pregnancy test screening . Women pregnant breastfeeding ineligible study Male subject must : 1 . Agree use condom throughout study drug therapy , dose interruption 3 month cessation study therapy partner childbearing potential contraception 2 . Agree donate semen study drug therapy 3 month end study drug therapy All subject must agree abstain donate blood take study drug therapy one week follow discontinuation study drug therapy All subject must agree share study medication another person return unused study drug investigator Absolute neutrophil Count ( ANC ) ≥ 1000/mm3 Platelets ≥ 100,000/mm3 ≥50,000/mm3 bone marrow involvement independent transfusion support either situation Alanine aminotransferase ( ALT ) aspartate aminotransferase ≤ 3 x upper limit normal ( ULN ) . Total bilirubin ≤ 1.5 x ULN unless bilirubin rise due Gilbert 's syndrome nonhepatic origin Serum creatinine ≤ 2 x ULN estimate Glomerular Filtration Rate ( CockcroftGault ) ≥ 40 mL/min/1.73 m2 Sign ( legallyacceptable representative must sign ) inform consent document indicate understand purpose procedure require study , include biomarkers , willing participate study Chemotherapy radiotherapy within 3 week , therapeutic antibody within 4 week , radioimmunotherapy within 10 week , major surgery within 4 week inclusion Known central nervous system lymphoma Other active malignancy Psychiatric illness condition could interfere subject ' ability understand requirement study Requirement corticosteroid therapy dose &gt; 10 mg prednisolone/day Major surgery within 4 week inclusion History stroke intracranial hemorrhage within 6 month prior inclusion Requirement anticoagulation treatment warfarin equivalent vitamin K antagonist ( eg , phenprocoumon ) Requirement treatment strong moderate CYP3A inhibitor Clinically significant cardiovascular disease uncontrolled symptomatic arrythmias , congestive heart failure , myocardial infarction within 6 month screen , Class 3 ( moderate ) Class 4 ( severe ) cardiac disease define New York Heart Association Functional Classification Vaccination live , attenuated vaccine within 4 week inclusion Known history human immunodeficiency virus ( HIV ) Active hepatitis C Virus Active Hepatitis B Virus infection uncontrolled Active systemic infection require intravenous antibiotic Any Lifethreatening illness , Medical condition , organ system dysfunction , investigator 's opinion , could compromise subject 's safety , interfere absorption metabolism ibrutinib capsule lenalidomide tablet , put study outcome undue risk Known hypersensitivity allergy rituximab , lenalidomide ibrutinib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Mantle cell lymphoma</keyword>
	<keyword>Relapsed mantle cell lymphoma</keyword>
	<keyword>Lenalidomide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Ibrutinib</keyword>
	<keyword>Response duration</keyword>
	<keyword>Complete remission rate</keyword>
	<keyword>Quality life</keyword>
	<keyword>Overall survival</keyword>
	<keyword>Safety</keyword>
</DOC>